# Lonvoguran Ziclumeran — In Vivo CRISPR Gene Editing in Hereditary Angioedema

- **DOI:** [10.1056/nejmoa2600931](https://doi.org/10.1056/nejmoa2600931)
- **Rating:** Strong (4.3 out of 5)
- **Verdict:** A single lonvo-z infusion delivers a large placebo-controlled reduction in hereditary angioedema attacks, but short follow-up leaves permanent-edit safety unresolved.
- **Framework version:** v5.10
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-11-02
- **Evaluation page:** https://www.nabu.science/paper/10.1056%2Fnejmoa2600931

## Key claims

1. Among patients with hereditary angioedema due to C1 inhibitor deficiency, a single dose of lonvo-z resulted in a significantly lower rate of hereditary angioedema attacks than placebo from 5 through 28 weeks after infusion.
   - Support: Well-supported
   - Type: Primary finding
   - Basis: prespecified randomized comparison with a large effect and consistent secondary efficacy findings
   - Location: Discussion, concluding paragraph
2. Patients in the lonvo-z group had a greater improvement in the AE-QoL total score from baseline to week 28 than those in the placebo group
   - Support: Supported
   - Type: Secondary
   - Basis: controlled improvement exceeds the stated clinical threshold, but week-28 arm counts remain unexplained
   - Location: Results, Key Secondary End Points; Table 2
3. 62% of the patients who received lonvo-z were considered by the investigator to be attack-free from weeks 5 to 28 without the use of long-term prophylaxis.
   - Support: Supported
   - Type: Secondary
   - Basis: reported counts support the percentage, but incomplete week-28 observation limits full-window attack-free interpretation
   - Location: Discussion, first paragraph
4. No serious or grade 3 or higher adverse events were reported in the lonvo-z group.
   - Support: Supported
   - Type: Secondary
   - Basis: systematic reporting supports observed events, but 52 treated patients and short follow-up limit detection of rare or delayed harms
   - Location: Abstract; Results, Safety; Table 3

## Strengths

- **Controlled evidence for a single infusion** The phase 3 comparison moves beyond earlier lonvo-z studies to demonstrate a large reduction in attacks under randomized, blinded placebo control.
  - Dimension: contribution
  - Location: Introduction; Results, Primary End Point; Table 2
- **Prespecified analyses and systematic harms collection** The endpoint hierarchy controls formal testing, and the primary model accounts for baseline attack frequency and follow-up duration. Harms reporting includes infusion reactions, liver enzymes, and event severity.
  - Dimension: methodological rigour
  - Location: Methods, Statistical Analysis; Results, Safety; Table 3
- **Safety uncertainties receive explicit contextual treatment** The discussion considers immunogenicity, hepatic events in other gene-editing programs, congenital kallikrein deficiency, and off-target effects. Its conclusion retains a potential-treatment framing rather than claiming established long-term safety.
  - Dimension: positioning
  - Location: Discussion, safety evidence and concluding paragraphs

## Limitations

- **Limited observation for a permanent intervention** The trial includes 80 patients with median follow-up of 7.5 months, and 16 had not reached week 28. These data cannot establish rare or delayed harms or long-term durability.
  - Dimension: methodological rigour
  - Location: Results, Patients; Discussion, limitations
- **Infusion reactions create a masking uncertainty** Infusion-related reactions occurred in 62% of lonvo-z recipients versus 18% of placebo recipients. With diary-based attack reporting, the absence of a reported blinding-success assessment leaves uncertainty about masking integrity.
  - Dimension: methodological rigour
  - Location: Methods, Clinical Assessment; Results, Safety; Table 3
- **Week twenty-eight denominators remain insufficiently reconciled** Results reports 43 lonvo-z and 21 placebo patients reaching week 28, whereas the AE-QoL footnote reports available data for 44 and 20. The shared total of 64 does not explain the arm-specific difference.
  - Dimension: reporting
  - Location: Results, Patients; Table 2 footnote ¶

## Reliability checks

Caveats (4 of 4 checks).

- **Results check:** Noted
  - Patients in the lonvo-z group had a greater improvement in the AE-QoL total score from baseline to week 28 than those in the placebo group: "data were available for 44 patients in the lonvo-z group and 20 patients in the placebo group" (Table 2, footnote ¶ (AE-QoL)) vs "A total of 64 patients (43 in the lonvo-z group and 21 in the placebo group) reached at least the week 28 evaluation" (Results, Patients). Comparing the reported arm counts gives 44/20 for AE-QoL availability versus 43/21 for week-28 evaluations, with the same total of 64 but an unexplained arm-specific difference. → Effect on result unclear
- **Reporting and transparency:** Clean. Ethics approval, written consent, trial registration, sponsor funding, and conflicts of interest are declared. Referenced external materials could not be independently inspected and do not establish a conduct concern.
  - Conflict of interest: declared · Ethics approval: declared · Preregistration: declared · Data availability: declared
- **Reference integrity:** Clean. 28 of 28 checkable references verified
  - 32 references in manuscript
  - 4 are books, websites or datasets — counted, but not index-checkable
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-11-02
